ADMA Biologics (ADMA) director awarded new RSUs and options

Rhea-AI Filing Summary

ADMA Biologics director Steve Elms reported new equity awards. On February 9, 2026, he acquired 10,690 restricted stock units of common stock at $0 and a stock option to buy 17,730 shares at $16.37, also valued at $0 on grant.

After these awards, he directly holds 98,020 shares of common stock (including RSUs) and 17,730 stock options. The filing also notes 2,031,730 shares of common stock held indirectly through Aisling Capital II LP, where he may be deemed a beneficial owner but disclaims beneficial ownership except for his pecuniary interest.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider ELMS STEVE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	17,730	$0.00	--
Grant/Award	Common Stock	10,690	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 17,730 shares (Direct); Common Stock — 98,020 shares (Direct); Common Stock — 2,031,730 shares (Indirect, See footnote)

Footnotes (1)

1. These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 81,885 shares of common stock owned by the Reporting Person. These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10-year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Issuer and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein. These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ELMS STEVE

(Last) (First) (Middle)

C/O AISLING CAPITAL MANAGEMENT LP

489 FIFTH AVENUE, 10TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		A		10,690(1)	A	$0	98,020(2)	D
Common Stock								2,031,730	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.37	02/09/2026		A		17,730		(4)	02/09/2036	Common Stock	17,730	$0	17,730	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.

2. Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 81,885 shares of common stock owned by the Reporting Person.

3. These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10-year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Issuer and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein.

4. These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

	/s/ Steve Elms, by Michael A. Goldstein as Attorney-in-fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ADMA director Steve Elms report on this Form 4 for ADMA?

Steve Elms reported receiving equity awards from ADMA Biologics. On February 9, 2026, he was granted 10,690 restricted stock units of common stock and a stock option covering 17,730 ADMA shares, both recorded at a grant price of $0 per unit or option.

How many ADMA Biologics RSUs and options did Steve Elms receive in the latest Form 4?

The filing shows a grant of 10,690 restricted stock units and a stock option for 17,730 shares of ADMA common stock. The RSUs and options were granted at a stated price of $0, with the option carrying an exercise price of $16.37 per underlying share.

What are the vesting terms for the new ADMA RSUs and stock options granted to Steve Elms?

The 10,690 RSUs vest in two equal installments at six and 12 months after the grant date, becoming fully vested after one year, subject to continued service. The 17,730 stock options vest in twelve equal monthly installments, also becoming fully vested on the one-year anniversary of the grant date.

What is Steve Elms’ direct ADMA Biologics share ownership after this Form 4 transaction?

After the reported grants, Steve Elms directly holds 98,020 shares of ADMA common stock, including his RSUs. He also directly holds 17,730 stock options. The footnotes specify that these totals incorporate current and prior RSU grants plus shares already owned by him.

What indirect ADMA Biologics holdings related to Steve Elms are disclosed for Aisling Capital II LP?

The Form 4 lists 2,031,730 ADMA common shares held indirectly through Aisling Capital II LP. Elms is associated with Aisling’s control entities and may be deemed a beneficial owner, but he expressly disclaims beneficial ownership of Aisling’s investment except to the extent of his pecuniary interest.

How long is the vesting period for the ADMA equity awards granted to Steve Elms?

Both new awards fully vest over one year from the February 9, 2026 grant date. The RSUs vest in two installments at six and 12 months, while the stock options vest monthly in twelve equal installments, all subject to his continued service with the company.